E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10061353 |
E.1.2 | Term | Pneumococcal infection |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the immune response 1 month after 2 doses of 13vPnC given 6 months apart compared to 1 month after 1 dose of 13vPnC as measured by fold rise in serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMC) in children with SCD who have previously been vaccinated with at least 1 dose of 23vPS. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the immune response 1 month after 2 doses of 13vPnC given 6 months apart compared to 1 month after 1 dose of 13vPnC as measured by serotype-specific IgG GMC in children with SCD who have previously been vaccinated with at least 1 dose of 23vPS. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male or female subject between the ages of ≥6 to <18 years. Diagnosis of SCD by hemoglobin electrophoresis or polymerase chain reaction (PCR); (HbSS, HbSC, HbSD, HbSE, HbSβ-thal). Documentation to show 23vPS vaccination at least 6 months prior to enrollment. Available for entire study period and whose parent/legal guardian can be reached by telephone. Subject and/or parent/legal guardian must be able to complete all relevant study procedures during study participation. Negative urine pregnancy test for female subjects who are postmenarche. All female and male subjects who are biologically capable of having children must agree to abstinence or commit to the use of a reliable method of birth control for the duration of the study and for 3 months after the last vaccination. |
|
E.4 | Principal exclusion criteria |
History of culture-proven invasive disease caused by S pneumoniae within the last year. Subject has/had a major illness or condition that, in the investigators judgment, will substantially increase the risk associated with the subjects participation in, and completion of the study. Subject has/had a major illness or condition that, in the investigators judgment, could preclude the evaluation of the subjects response to vaccination. History of hematopoietic stem cell transplantation. Previous vaccination with pneumococcal conjugate vaccine. Has a dose of 23vPS recommended between enrollment and the blood draw at visit 4. Previous anaphylactic reaction to any vaccine or vaccine-related component. Contraindication to vaccination with pneumococcal conjugate vaccine. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection. Receipt of immunoglobulin infusion or injection during the 42 days preceding enrollment. Known or suspected immune deficiency or suppression. Pregnant or breast feeding female. Participation in another investigational trial from 28 days before enrollment until the end of the study. (Note: participation in purely observational studies is acceptable.) Subject is a direct descendant (child or grandchild) of a member of site study personnel or is study personnel. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The GMFR in IgG concentration is the primary analysis endpoint following dose 2 relative to dose 1 for each serotype. This will be summarized for subjects having data following both doses using a 95% confidence interval. Separate summaries will be produced for GMCs at each dose, prior to each dose, for the GMFR at each dose, and for the difference in GMFR between doses. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |